Drug Trial Radar · NCT07569640
HFrEF Polypill in Sri Lanka RCT
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,672
Planned (sponsor's estimate)
Start
Aug 17, 2026
Primary completion
Apr 2029
Study completion Apr 2029
Sponsor
- Lead sponsor
- Washington University School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Centre for Chronic Disease Control, India; National Heart, Lung, and Blood Institute (NHLBI); RemediumOne (Pvt) Ltd.; University of Kelaniya; The George Institute
- First posted
- May 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to evaluate, in adults with HFrEF in Sri Lanka, the effects of an HFrEF polypill implementation strategy on the composite rate of cardiovascular disease mortality and recurrent heart failure hospitalizations, compared with usual care over a minimum of 12-months of follow-up. Primary outcome of the study: 1\) Composite rate of cardiovascular disease mortality and recurrent heart failure hospitalizations over study duration Secondary outcomes of the study: 1. Rate of cardiovascular disease mortality over study duration 2. Rate of recurrent heart failure hospitalizations over the study duration 3. Rate of all-cause mortality over the study duration 4. Change in left ventricular ejection fraction at 12-months and end of study assessed by transthoracic echocardiogram 5. Change in BNP levels at 12 months and end of study 6. Change in overall and domain specific health-related quality of life at 12-months and end of study assessed by a translated validated version of the Kansas City Cardiomyopathy Questionnaire (KCCQ-23) 7. Change in physician-reported New York Heart Association class at 12-months and end of study 8. Adherence to guideline-directed medical therapy assessed by pill count and MARS-5 questionnaire at baseline, 1-, 6-, 12-months, and end of study. Persistence assessed as continuation of assigned therapy at each follow-up visit. Dose optimization assessed as proportion achieving target doses (Strength 3 of the polypill, or comparable individual GDMT doses in the comparator arm) at 6-, 12-months, and end of study. Safety outcomes: 1. Proportion of participants with serious adverse events according to Good Clinical Practice guidelines over study duration 2. Proportion of participants with adverse events of special interest over study duration 3. Proportion of participants with adverse events leading to HF drug discontinuation over study duration 4. Mean change from baseline to 12-months and end of study in serum potassium (mEq/L) 5. Mean change from baseline to 12-months and end of study in serum creatinine (mg/dL) Participants will be randomly assigned 1:1 stratified by sex and site to one of two groups, intervention (experimental arm) or usual care (control arm). The intervention group will be given four guideline-recommended medications for heart failure with reduced ejection fraction, combined in one over-encapsulated pill, with three dose strength options. Both groups will be observed over a minimum of 12-months of follow-up to assess key outcomes.
Conditions
- Heart Failure With Reduced Ejection Fraction
Interventions
Usual CareOther
Participants in the comparator control group will receive usual care from their healthcare providers. Providers will be encouraged to treat all participants according to international and local clinical practice guidelines. Participants will receive their HFrEF medications through the pharmacy at the sites, where guideline-directed medical therapy are dispensed without charge to participants when available on the public hospital formulary.
HFrEF PolypillDrug
The study intervention is a HFrEF polypill consisting of bisoprolol (beta-blocker), losartan (ARB), eplerenone (MRA), and dapagliflozin (SGLT2i) manufactured using the over-encapsulation method. There will be 3 strengths of the HFrEF polypill available: Strength 1: bisoprolol 2.5 mg + losartan 25 mg + eplerenone 25 mg + dapagliflozin 10 mg Strength 2: bisoprolol 5 mg + losartan 50 mg + eplerenone 25 mg + dapagliflozin 10 mg Strength 3: bisoprolol 10 mg + losartan 100 mg + eplerenone 50 mg + dapagliflozin 10 mg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite rate of cardiovascular disease mortality and recurrent heart failure hospitalizations over study durationTime frame: 1 month, 3 month, 6 month, 9 month, 12 month study visits, and every 3 months thereafter through study completion, an average of 18 months.
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
National Hospital Kandy
Kandy, Central Province, Sri Lanka · Recruiting
Teaching Hospital Anuradhapura
Anuradhapura, North Central Province, Sri Lanka · Not yet recruiting
Teaching Hospital Kurunegala
Kurunegala, North Western Province, Sri Lanka · Recruiting
Teaching Hospital Jaffna
Jaffna, Northern Province, Sri Lanka · Recruiting
Rathnapura Teaching Hospital
Colombo, Ratnapura, Sri Lanka · Recruiting
National Hospital Galle
Galle, Southern Province, Sri Lanka · Recruiting
National Hospital of Sri Lanka
Colombo, Western Province, Sri Lanka · Recruiting
University Hospital - General Sir John Kotelawala Defence University
Colombo, Western Province, Sri Lanka · Not yet recruiting
Colombo South Teaching Hospital
Dehiwala, Western Province, Sri Lanka · Recruiting
Gampaha District General Hospital
Gampaha, Western Province, Sri Lanka · Recruiting
District General Hospital Negombo
Negombo, Western Province, Sri Lanka · Recruiting
Colombo North Teaching Hospital
Ragama, Western Province, Sri Lanka · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.